Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Myeloma • NCI-CCC Tumor Board Question • Mayo Clinic • NCI-CCC Myeloma Tumor Board Question
Do you recommend utilizing daratumumab in the maintenance phase after a quadruplet induction for transplant eligible multiple myeloma?
Answer from: Medical Oncologist at Academic Institution
Great question as always - both the Phase 2 GRIFFIN study (Dara-VRd vs VRd using IV Dara and 21-day induction cycles) and the Phase 3 PERSEUS study (Dara-VRd vs VRd using subQ dara and 28-day induction cycles) went on to use dara + lenalidomide for all patients in the post-transplant maintenance set...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Dr. @Banerjee has summarized the data well. The phrase "standard-risk cytogenetics" has not aged well, and I am hoping that more precise language will be more commonplace, incorporating the influence of increased LDH, 1q+, del 1p, circulating plasma cells, etc.While Dara+Len is not yet as well suppo...
Answer from: Medical Oncologist at Academic Institution
I think Dr. @Banerjee has summarized things well. One additional point I will make is that the Emory group presented on a very large series of patients treated with Dara-VRd and transplant, after which standard-risk patients received only lenalidomide and high-risk patients received a PI/IMiD. The P...
Answer from: Medical Oncologist at Academic Institution
The trials that we use to guide our practice for using daratumumab in newly diagnosed transplant eligible myeloma (PERSEUS and GRIFFIN prior to that), do not isolate the role of daratumumab in induction versus maintenance. A trial that isolated the role of any maintenance in the era of quads (CASSIO...